Silence Therapeutics Plc American Depository Share closed at $19.80 on Nov 12, up 0.15% — matching its 52-week closing high. Volume of 659.2K shares was 0.11× its 20-day average (below normal).
Split-adjusted performance: +120.5% over one month, +177.7% over six months, +194.6% over one year.
Short interest was 2.4M shares at the Oct 30 settlement, down 17.4% from the prior report (1.0 days to cover).
No reported quarters with price history yet.
Percentile among 419 companies (100 = best)
Industry medians: 6-month return −26.6%, revenue growth +10.0%, net margin −36.2%, P/E 17.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SLNSilence Therapeutics Plc American Depository Share | $19.80 | +0.15% | +177.7% | — | — | — | $1.23B | |
| CMPSCOMPASS Pathways Plc American Depository Shares | $9.12 | −1.94% | −14.1% | — | — | — | $1.29B | Compare |
| GPCRStructure Therapeutics | $19.84 | −5.30% | −50.2% | — | — | — | $1.41B | Compare |
| AMRNAmarin | $11.67 | −0.34% | −21.0% | −20.4% | 0.6% | — | $490.6M | Compare |
| ZLABZai Lab Limited | $26.04 | −1.44% | +28.1% | −6.8% | −42.6% | — | $3.23B | Compare |
| BCYCBicycle Therapeutics | $3.45 | −6.50% | −26.1% | +190.2% | −30.8% | — | $241.8M | Compare |
| KZIAKazia Therapeutics Limited | $6.95 | −6.46% | −49.7% | — | — | — | $108.1M | Compare |
| MREOMereo BioPharma Group | $0.3050 | −0.52% | +24.0% | — | — | — | $48.7M | Compare |
| ONCBeOne Medicines | $415.96 | −0.96% | +36.6% | +33.8% | 20.4% | 51.9 | $47.51B | Compare |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
